Not exact matches
I have also pursued clinical and research interests in nutrition and
cancer prevention, and the treatment of
advanced esophageal and pancreatic
cancers.
Ramuacirumab (CYRAMZA ®), an anti-VEGFR2 targeted antibody, is also appproved for
esophageal cancer patients, while pembrolizumab (Keytruda ®), an anti-PD-1 checkpoint immunotherapy, is approved for patients with
advanced cancers of the gastroesophageal junction that express PD - L1.
Currently, the CDK9 inhibitor flavopiridol is being evaluated in several phase I and II clinical trials for its anti-
cancer effects either as a single agent or in combination with other drugs in treatment of
esophageal cancer, B - cell chronic lymphocytic leukemia, endometrial carcinoma, recurrent / metastatic squamous cell carcinoma and most relevantly, previously treated locally
advanced or metastatic breast
cancer (http://www.cancernetwork.com/review-article/current-clinical-trials-flavopiridol/page/0/2).
Interventional gastroenterology including endoscopic ultrasound, ERCP, treatment of
esophageal varices, and placement of endobiliary stents for palliation in patients with
advanced biliary
cancers